- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Urology
- Hospital Affiliation
- The Mount Sinai Hospital
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Tumors
- Urologic Cancers
Residency, Internal Medicine
Beth Israel Deaconess Medical Center- Harvard Medical School
Fellowship, Medical Oncology
Memorial Sloan-Kettering Cancer Center
American Society of Clinical Oncology Merit Award
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
Alpha Omega Alpha Honor Society
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel,
The purpose of this study is to:
- Test the safety of the research study drug, pembrolizumab (also called MK-3475)
- Test the effectiveness of the research study drug pembrolizumab compared to paclitaxel or docetaxel or vinflunine for recurrent/progressive me...
The purpose of this study is to look at the effects, good or bad, of an experimental drug called MPDL3280A on you and your bladder cancer. An experimental dr...
Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
The purpose of this study is to see the safety and effectiveness of Everolimus when given alone or when given in combination with Paclitaxel. Paclitaxel is the standard treatment that is routinely given to patients with your condition. Everolimus is an investigational drug, which...
Metformin - Rising PSA Remote Trial (M-RePoRT)
When prostate cancer has spread to other parts of the body (metastasized), and can be seen on tests like CT scans and bone scans, the standard treatment is to lower a man's testosterone level with medication (or less commonly, surgery to remove the testicles). it is not cur...
A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow...
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
The purpose of this study is to compare the good and bad effects of pembrolizumab to a placebo in people with metastatic or unresectable bladder cancer that responded after initial chemotherapy. in this study, you will get either pembrolizumab or placebo. A placebo is...
You are being given information about becoming a volunteer in a research study. You may qualify to partici...
A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGFR kinase inhibitor, in adult patients with advanced solid malignancies
The primary objective of this study is to find out which is the highest dose of BGJ398 that can be given safely to patients. The secondary objectives of the study are to understand what BGJ398 does to your body and assess what your body does to clear the drug from your system....
A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer
The purpose of this study is to evaluate the effects of abiraterone acetate on prostate cancer in African American/Black men and will determine if difference in genes measured in the blood impact the likelihood of prostate cancer to respond to treatment with abiraterone acetate. ...
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow ...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Galsky during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- BioMotiv, LLC
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Dual Therapeutics
Scientific Advisory Board:
- Astellas Pharma Inc.
- Merck & Co., Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.